Read by QxMD icon Read


Agnieszka Kraszewska, Katarzyna Ziemnicka, Jerzy Sowiński, Ewa Ferensztajn-Rochowiak, Janusz K Rybakowski
INTRODUCTION: The studies on the effect of lithium treatment on antithyroid antibodies showed either a higher concentration of these antibodies in patients receiving lithium compared to those lithium-naive or no difference between these groups. In lithium-treated bipolar patients, some researchers pointed to an association between antithyroid antibodies and other features of thyroid dysfunction such as hypothyroidism and decrease of glomerular filtration rate. METHODS: We compared antithyroid antibodies in 98 patients (30 male, 68 female) with bipolar disorder, aged 62±13 years, who received lithium for 19±10 years to 39 patients (12 male, 27 female), aged 57±10 years, who were never treated with lithium...
February 7, 2019: Pharmacopsychiatry
Anton J M Loonen, Svetlana A Ivanova
Recently, in a review article in this journal, Vlček and colleagues described the putative role played by the glutamatergic system in obsessive-compulsive disorder (OCD) and how this might explain the effects of certain treatments. They describe a neuroanatomical model, which includes a specific role of the amygdala-hippocampus complex (AHC) and would complete the classic cortico-striatal-thalamo-cortical (CSTC) mechanism of OCD. The role of the AHC can perhaps be better understood when considering its ancient relationship to the rest of the forebrain of mammals...
February 4, 2019: Pharmacopsychiatry
Samia Tasmim, Nathan J Kolla, Oluwagbenga Dada, Ali Bani-Fatemi, Vincenzo De Luca
INTRODUCTION: Violent behavior is more common in individuals with schizophrenia, compared to the general population. Studies suggest higher psychotic symptoms are predictive of greater violent behavior. On the other hand, violent behaviors are reduced with antipsychotic treatment. However, the relationship between antipsychotic dosage and violence has not been studied to date. Thus, we aimed to determine if there exists an association between antipsychotic dosage and violence scores and whether the maximum violence would be predictive of the final antipsychotic dosage...
January 22, 2019: Pharmacopsychiatry
Sahar Latifi, Thomas Messer
The combination of tiapride (TIA) and carbamazepine (CBZ) as an alternative treatment option to benzodiazepines and clomethiazole has been investigated by several investigations. We performed a systematic review and meta-analysis to further explore the efficacy of this combination in order to render more definite answers whether this combination can be recommendable in the clinical practice. We systematically searched electronic databases including PubMed (MEDLINE), EMBASE, OVID, Cochrane, Google Scholar, and Scopus for human studies...
December 6, 2018: Pharmacopsychiatry
F Markus Leweke, Stefan Bleich, Udo Schneider
No abstract text is available yet for this article.
December 3, 2018: Pharmacopsychiatry
Xiao-Qian Lin, Ping Wang, Wen-Ke Cai, Gui-Li Xu, Mei Yang, Meng-Di Zhou, Mei Sun, Fang He, Gong-Hao He
BACKGROUND: The association between CYP2D6 metabolizer status and clinical outcomes of venlafaxine was extensively investigated previously, but no widely accepted conclusion has been reached so far. To obtain a more precise estimation of the association, a systematic review by meta-analysis was conducted in the present study. METHODS: The PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Technology of Chongqing, and Wan Fang Database were searched for eligible studies up to August 2018...
November 28, 2018: Pharmacopsychiatry
(no author information available yet)
No abstract text is available yet for this article.
January 2019: Pharmacopsychiatry
Andrei Miclea, Marius Miclea, Maximilian Pistor, Katharina Stegmayer, Robert Hoepner
INTRODUCTION: Substantial evidence has indicated an association between hypogonadism and depressive symptoms, which led to the conduction of studies that found an ameliorating effect of testosterone (T) supplementation (S) upon depression in men. METHODS: Retrospective analysis of medical records identified 16 depressed, hypogonadal men who have not responded adequately to initial antidepressant therapy and subsequently received intramuscular T injections. Following the proposal of Button et al...
November 2018: Pharmacopsychiatry
Theresa Dembler-Stamm, Jana Fiebig, Andreas Heinz, Jürgen Gallinat
INTRODUCTION: Sexual dysfunction figures prominently in patients with schizophrenia; however, medication effects may play a role. The objective of this case control study was to assess differences in the presence of sexual dysfunction in unmedicated patients with schizophrenia versus healthy controls. METHODS: Sexual dysfunction was assessed using the Derogatis Inventory for Sexual Function self-rating in a cross-sectional design controlling for age and gender effects...
November 2018: Pharmacopsychiatry
Lisa Proebstl, Felicia Kamp, Gabi Koller, Michael Soyka
Methamphetamine use has spread in many European countries and the United States. The current review provides a summary and critical analysis of research on cognitive deficits associated with methamphetamine, also known as "crystal meth." The literature search performed for this review led us to the hypothesis that methamphetamine use is associated with persistent changes in brain metabolism that result in various impairments, such as deficits in memory, attention, and concentration. The dopaminergic system in particular seems to be affected...
November 2018: Pharmacopsychiatry
Sara Baldelli, Emilio Clementi, Dario Cattaneo
The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines...
November 2018: Pharmacopsychiatry
Atieh Modarresi, Mehdi Sayyah, Setareh Razooghi, Kaveh Eslami, Mohammadreza Javadi, Leila Kouti
INTRODUCTION: There is a large body of evidence on the clinical benefits of augmentation therapy with glutamate-modulating agents, such as memantine in reducing OCD symptoms. METHODS: A double-blind, placebo-controlled trial was conducted on SRIrefractory OCD patients. Thirty-two patients were randomized to receive either 20 mg/day memantine or placebo augmentation and were visited at baseline and every 4 weeks for 12 weeks. Results were measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)...
November 2018: Pharmacopsychiatry
Přemysl Vlček, Jakub Polák, Martin Brunovský, Jiří Horáček
Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Although its pathogenesis remains unclear, the traditional model focused on alternations in the serotonin system. Selective serotonin reuptake inhibitors provide the most effective treatment; however, as much as 40-60% of patients do not respond to antidepressants therapy. Thus, attention has shifted towards other neurotransmitter systems and related neuroanatomical structures...
November 2018: Pharmacopsychiatry
Georgios Schoretsanitis, Alejandro G Villasante-Tezanos, Jose de Leon
No abstract text is available yet for this article.
October 22, 2018: Pharmacopsychiatry
Rebecca Schennach, Michael Riedel, Ilja Spellmann, Richard Musil, Michael Obermeier, Markus Jäger, Roland Bottlender, Max Schmauss, Gerd Laux, Hans-Jürgen Möller
INTRODUCTION: The aim of this double-blind randomized study was to evaluate the response to antipsychotic treatment in schizophrenia patients with predicted high/low risk of nonresponse identified by applying a set of well-established scales and predictors of outcome and to compare efficacy between ziprasidone and haloperidol. METHODS: One hundred twelve schizophrenia patients (ziprasidone: n=54; haloperidol: n=58) were rated weekly on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), the Global Assessment of Functioning Scale (GAF), the Social and Occupational Functioning Scale (SOFAS), the Simpson-Angus Scale (SAS), and Hillside Akathisia Scale (HAS)...
September 20, 2018: Pharmacopsychiatry
Ewa Kurczewska, Ewa Ferensztajn-Rochowiak, Anna Jasińska-Mikołajczyk, Maria Chłopocka-Woźniak, J K Rybakowski
INTRODUCTION: The aim was to assess the efficacy of total sleep deprivation (TSD) with sleep phase advance (SPA) in treatment-resistant depression (TRD) and associated biochemical factors. METHODS: We studied nine males and 12 females, aged 49±14 years, with treatment-resistant unipolar or bipolar depression, receiving antidepressant and mood-stabilizing drugs. The four-day schedule included single TSD and three consecutive nights with SPA. Biochemical markers were measured on the day before and on 1st, 7th and 14th day after the TSD...
September 10, 2018: Pharmacopsychiatry
Marylou Selo
No abstract text is available yet for this article.
September 2018: Pharmacopsychiatry
Michael Bauer
No abstract text is available yet for this article.
September 2018: Pharmacopsychiatry
Frank Bellivier, Cynthia Marie-Claire
Lithium (Li) is the key mood stabilizer in the prevention of mood recurrences and suicide in bipolar disorders. However, only one-third of patients become asymptomatic with Li treatment, and to date, no clinical markers can predict this response variability. Li is a multitargeting drug, complicating an understanding of its mechanisms of action. The present article reviews Li's various biological effects, including those obtained in transcriptomic and epigenetic studies, in both humans and animal models. A molecular signature of the therapeutic response to Li is urgently required, including possibly from the circulation...
September 2018: Pharmacopsychiatry
Werner Felber, Michael Bauer, Ute Lewitzka, Bruno Müller-Oerlinghausen
Although lithium's serendipitous discovery as a medication for depression dates back more than 200 years, the first scientific evidence that it prevents mania and depression arose only in the 1960s. However, at that time there was a lack of knowledge about how to administer and monitor lithium therapy safely and properly. The lithium clinics in Dresden and Berlin were remarkably similar in their beginnings in the late 1960s regarding patient numbers and scientific expertise without being aware of one another due to the Iron Curtain separating Germany into a western and eastern part until 1990...
September 2018: Pharmacopsychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"